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Background: Soft tissue sarcomas are heterogeneous and a major complication in their management is that the existing
classification scheme is not definitive and is still evolving. Leiomyosarcomas, a major histologic category of soft tissue sarcomas,
are malignant tumours displaying smooth muscle differentiation. Although defined as a single group, they exhibit a wide range of
clinical behaviour. We aimed to carry out molecular classification to identify new molecular subgroups with clinical relevance.
Methods: We used gene expression profiling on 20 extra-uterine leiomyosarcomas and cross-study analyses for molecular
classification of leiomyosarcomas. Clinical significance of the subgroupings was investigated.
Results: We have identified two distinct molecular subgroups of leiomyosarcomas. One group was characterised by high
expression of 26 genes that included many genes from the sub-classification gene cluster proposed by Nielsen et al. These
sub-classification genes include genes that have importance structurally, as well as in cell signalling. Notably, we found a
statistically significant association of the subgroupings with tumour grade. Further refinement led to a group of 15 genes that
could recapitulate the tumour subgroupings in our data set and in a second independent sarcoma set. Remarkably, cross-study
analyses suggested that these molecular subgroups could be found in four independent data sets, providing strong support for
their existence.
Conclusions: Our study strongly supported the existence of distinct leiomyosarcoma molecular subgroups, which have clinical
association with tumour grade. Our findings will aid in advancing the classification of leiomyosarcomas and lead to more
individualised and better management of the disease.
Adult soft tissue sarcomas are malignant tumours that occur in
connective tissues throughout the body, other than the bone or
cartilage (Goldblum et al, 2014). Major histologic categories of soft
tissue sarcomas include leiomyosarcoma (smooth muscle differ-
entiation), liposarcoma (fatty differentiation), rhabdomyosarcoma
(striated muscle differentiation), synovial sarcoma and undiffer-
entiated pleomorphic sarcoma. These tumours are heterogeneous
and a major complication in the management of this disease is that
the existing classification scheme is not definitive and is still
evolving. Leiomyosarcomas are malignant tumours with smooth
muscle differentiation that are defined as a single group based on
the morphology and immunohistochemical examination, although
exhibiting a wide range of clinical behaviour that correlates to
some extent with histological grade (Goldblum et al, 2014).
Gastrointestinal stromal tumour (GIST) was historically classified
as gastrointestinal leiomyosarcoma before the identification of
activating mutations in KIT by Hirota et al (1998) and the
immunohistochemical association, with interstitial cells of Cajal by
Kindblom and others (Kindblom et al, 1998) in the late 1990s.
Advances in molecular understanding and techniques clearly
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distinguished GIST from leiomyosarcoma, and with the advent of
imatinib therapy this became a paradigm for the molecularly
targeted treatment of cancer (Verweij et al, 2004; Bauer and
Joensuu, 2015; Nishida et al, 2015). This clearly illustrates the
importance of improving the classification of sarcomas and the
beneficial effect this can have on disease management and patient
outcome. With further advances in modern molecular techniques,
it is hoped that we would be able to better molecularly classify the
tumours into subgroups, which may eventually lead to improved
management of the disease. To this end, we have used microarray
gene expression profiling to study the expression pattern of
leiomyosarcomas, with the aim of improving its molecular
classification and identifying new molecular subgroups that may
be of clinical relevance. We have focused on leiomyosarcomas of
extra-uterine origin in this study, as uterine leiomyosarcoma
represents a relatively distinct clinical entity and can be easily
identified from its site of origin (Amant et al, 2009; Linch et al,
2014). Our findings provide important support to the initial
findings of Nielsen et al (2002) in an independent sarcoma set.
Nielsen et al (2002) used microarrays to molecularly character-
ise 41 soft tissue tumours that included some leiomyosarcomas and
GISTs, as well as tumours of other histologic categories. They
noted a distinct gene expression pattern of the GISTs that was
distinct from the leiomyosarcomas. Eleven leiomyosarcomas were
included in their study, and they found initial evidence of
separation of leiomyosarcomas into two subgroups, one group
characterised by the high expression of a group of 24 gene,
representing 20 distinct genes that included the gene for Calponin
and other genes implicated in muscle structure and function.
Recently, coinciding with our investigations, other studies also
suggested the existence of subtypes of leiomyosarcoma (Beck et al,
2010; Guo et al, 2015). In this study, we further investigated the
molecular classification of leiomyosarcomas and the clinical
relevance of the new classification.
MATERIALS AND METHODS
Microarray procedures. Leiomyosarcoma is a relatively rare form
of cancer. Sarcoma tissue samples used in this study were collected
from patients undergoing surgery at two hospitals (the Royal
Marsden NHS Foundation Trust, London and the Royal
Orthopaedic Hospital NHS Foundation Trust, Birmingham) that
treat significant numbers of sarcoma patients in the UK over the
period of 1987–2001. Diagnoses were performed by experienced
sarcoma pathologists using conventional criteria, including immu-
nohistochemistry and electron microscopy, if appropriate. This
study was conducted with the approval of our local Research Ethics
Committee. Clinicopathologic descriptions of the cases are shown
in Supplementary Table S2. (Summary patient characteristics:
median age¼ 61 years; sex (M¼ 58% and F¼ 42%); location
(extremity¼ 58%, non-extremity (thoracic/abdominal/retroperito-
neal sites)¼ 42%); and tumour size (5 cm or less in greatest
dimension¼ 21%, 45 cm in greatest dimension¼ 79%).) The
tumour samples were snap-frozen in liquid nitrogen and stored at
–80 1C until RNA extraction. Tumour and control RNA prepara-
tion were performed as in Lee et al (2003), except that HB4a was
not included in the control RNA. Microarray slides were gridded
with 11 622 spots, consisting of 1937 I.M.A.G.E cDNA clones
(gridded six times each) acquired from the UK Human
Genome Mapping Project Resource Centre and Research Genetics
(http://www.resgen.com). The majority of the clones included were
selected at random, except for the 23 gene probes that
corresponded to 18 of the distinct genes reported by Nielsen
et al (2002), as described below. We were unable to get hold of the
clones that corresponded to the other two of the 20 distinct genes
that distinguished their leiomyosarcoma samples into the two
subgroups. Information on the gene set can be found at the
Supplementary Table S1 (array data to be found on Gene Expression
Omnibus (GEO) GSE76216). The preparation of the microarray
slides, including gridding and blocking were as described in Clark et al
(2002), except that the BioRobotics Microgrid II (BioRobotics,
Cambridge, UK) was used for gridding in this study. RNA labelling
was performed as in Lee et al (2003), except that after the final wash
with 400ml 0.5 SSPE, the sample was reduced to a volume of 4ml.
Microarray hybridisation was performed as in Lee et al (2003)
except the following: after the coverslip fell off, the slide was then
washed with 4 SSPE, 10mM EDTA for 1min at 42 1C; then 50%
formamide, 6 SSPE at 42 1C for 15 s with gentle rocking;
then 2 SSPE, 10mM EDTA for 30 s at room temperature; and
0.1 SSPE for 30 s at room temperature. The slide was then rinsed
briefly with HPLC grade water and dried with canned air.
Hybridised microarray slides were scanned in a GenePix 4000B
scanner (Axon Instruments, Foster City, CA, USA) as described
before (Lee et al, 2004) and slides were scanned at photomultiplier
tube voltage levels that provided a Cy5 : Cy3 hybridisation ratio
across the slide of roughly 1.
Analysis of microarray data. Data processing and analyses were
performed with the GenePix Pro software (Axon Instruments,
Foster City, CA, USA) and the GeneSpring software (Silicon
Genetics, Redwood City, CA, USA). Background determination
and flagging were performed as described before (Lee et al, 2004).
Further quality filtering was performed by excluding spots with
fluorescent spot intensity in the control channel being o1.4 times
the local background of that channel. Ratios of fluorescent
intensities (Cy5 : Cy3) for individual cDNA were then determined
after subtraction of background as described before (Lee et al,
2004), except that the average fluorescent intensity ratios of
replicate spots were used. These ratios were then normalised by
making the median of all measurements in each sample to be 1.
The resulting ratios were further normalised so that the median of
all measurements taken for a particular gene is 1. To obtain genes
that showed variation in expression among the tumours, a subset
of genes that had normalised expression ratios of 42 in at least
five of the samples or o0.5 in at least five of the samples were
selected. Hierarchical clustering was then applied to the log-
transformed data for these genes and the tumours, using average-
linkage clustering with Pearson correlation around zero as the
similarity metric. Only genes with expression data present in half
or more of the tumour samples, following quality filtering were
included in the gene clustering. Clustering analysis was also
performed with the ‘leio-subclass’ genes from Nielsen et al (2002)
present in our array, as well as gene clusters identified from our
data set. Class comparison analysis (BRB array tools) using two
sample t-test and multivariate permutations test computed based
on 1000 random permutations (confidence level of false discovery
rate assessment: 80%; maximum allowed proportion of false-
positive genes: 0.1) was carried out to identify statistically
significant genes associated with the group I and II tumours.
Gene expression data of the 17 leiomyosarcomas reported in the
study by Baird et al (2005) were downloaded from GEO data
repository. Array data normalisation and clustering analysis were
performed as described above.
Other statistical analyses including Kendall’s taub for assessing the
significance of association between tumour subgroupings and tumour
grade were performed using SPSS (SPSS Inc, Chicago, IL, USA).
RESULTS
The expression profiles for 20 leiomyosarcomas were investigated
using cDNA microarrays. To better explore the expression
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differences that may exist between the different tumours, a subset
of 169 genes that showed the most variation in expression among
the tumours was used in the cluster analysis. Hierarchical
clustering using these most varied genes in this set of tumours
gave rise to two clusters of tumours (Figure 1), one group (group I)
was characterised by higher expression of a cluster of 26 genes. Ten
of these genes were also found in the 20 distinct genes reported by
Nielsen et al (2002). In making this array, we have mined the
expression data from Nielsen et al (2002) and have specifically
included clones that corresponded to all except 2 of the 20 distinct
genes from Nielsen et al (2002) (‘leio-subclass’ genes) that
distinguished their leiomyosarcoma samples into the two sub-
groups that they called the ‘Calponin’ subgroups (Supplementary
Table S1). This allowed us to specifically carry out clustering
analysis using the expression of these ‘leio-subclass’ genes (23 gene
probes corresponding to 18 of the distinct genes reported by
Nielsen et al (2002)). Hierarchical clustering analysis on the
tumours, using these 23 ‘leio-subclass’ genes representing 18
distinct genes gave rise to two groups of tumours, with one
group of tumours exhibiting high level of expression of these genes
(called ‘Calponin-positive’ group by Nielsen et al (2002); Figure 2).
Gene clustering was also carried out for the 12 of these genes that
satisfied the criteria for use in gene clustering (Figure 2).
We repeated tumour clustering analysis, using only the cluster
of 26 genes that defined the groupings in the ‘most varied genes’
analysis, and the result showed two distinct clusters of tumours
(Figure 3), with a well-defined cluster of eight tumours (group I)
that matched exactly with the tumours identified to be ‘Calponin
positive’ using the ‘leio-subclass’ genes.
The group I tumours were defined by the high expression of this
cluster of 26 genes (Table 1). We noted that 10 of the ‘leio-subclass’
genes were present in the most varied genes (169 genes), and
remarkably, all 10 of these 10 ‘leio-subclass’ genes were found in this
cluster of 26 genes. The 16 additional genes that were new to the ‘leio-
subclass’ gene cluster were also shown in Table 1, and included a
number of genes that have structural importance for plasma
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Figure 1. Two-dimensional cluster analysis of leiomyosarcomas (horizontal) and most varied genes (vertical). Each column corresponds to a
tumour and each row corresponds to a gene. Red indicates overexpression, whereas green indicates underexpression. Grey indicates missing or
excluded data. Asterisk indicates the tumour belongs to group I in clustering analysis of Figure 2.
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membrane (EVI2B), basement membrane (COL4A2; COL4A1
and NID1) and in extracellular matrix (MFAP4); cell adhesion
(CDH1; ITGA1); as well as genes that have important functions like
cell signalling (JAG1 involved in Notch signalling; GNAZ in
transmembrane signalling; and PTCH1 in hedgehog and other
signalling).
We then looked into the clinical relevance of these subgroups of
tumours. Analysis of relevant clinical data showed a statistically
significant association of the subgroupings with tumour grade (Kendall’s
taub 0.650, Po0.01; Table 2). Group I was found to be associated with
the lower tumour grade. We have not found any statistically significant
association of the cluster grouping with other clinical parameters
(tumour size (p5cm or 45cm), site (superficial or deep), location
(extremity or non-extremity), stage (I–IV) or tumour status (primary,
local recurrence or metastasis); Supplementary Table S2).
We noted that a cluster of 15 genes were best associated with the
subgroupings of tumours and may allow us to further refine
the gene list, so these were tested to see if they could recapitulate
the subgroupings of tumours (Table 1). We performed clustering
analysis with this group of 15 genes and found that the tumours
were clustered in the same two groups as with the use of the larger
gene clusters; one group was defined by the high expression of
these genes (Supplementary Figure S1). We further validated the
use of this group of 15 genes in an independent sarcoma set that
has not been used for identifying subgroups. We downloaded and
analysed the gene expression data of the 17 leiomyosarcomas in the
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Figure 2. Hierarchical clustering analyses of leiomyosarcomas (vertical) and the ‘leio-subclass’ genes in our array (horizontal). Each row
corresponds to a tumour and each column corresponds to a gene. Red indicates overexpression, whereas green indicates underexpression. Grey
indicates missing or excluded data. Asterisk indicates the tumour belongs to group I in this clustering analysis.
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sarcoma study by Baird et al (2005). Thirteen of the genes in their
data set were mapped to genes found in our group of 15 genes and
clustering analysis was performed accordingly. We found that
these genes also defined a subgroup of tumours (10) that had high
expression of these genes.
There was also interest in identifying potential targets
for therapy associated with the two subgroups, particularly as
they were found to be clinically relevant. Class comparison
analysis using two sample t-test and multivariate permutations
test was performed to identify statistically significant genes
associated with our two subgroups. The statistically significant
genes were compared with the genes from the TARGET V3
database (Allen et al, 2014) that contains over 130 genes
at present, which are believed to have therapeutic, prognostic
and diagnostic implications for cancer patients, and are of
particular interest in translational oncology. Our comparison
showed that two of the genes (CDH1 and PDGFRA) in our gene
list are found in these TARGET genes and may be potential
subgroup-specific targets. The high expression of CDH1
is associated with group I tumours. This gene has been reported
to be of diagnostic value and is frequently mutated in lobular
breast carcinoma and in certain hereditary cancer syndromes,
including a type of gastric cancer (Allen et al, 2014). The high
expression of PDGFRA is associated with group II tumours, and
is associated with the sensitivity to tyrosine kinase inhibitors
(Allen et al, 2014).
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Figure 3. Hierarchical clustering analyses of leiomyosarcomas (vertical) and the 26 genes (horizontal). Each row corresponds to a tumour and
each column corresponds to a gene. Red indicates overexpression, whereas green indicates underexpression. Grey indicates missing or excluded
data. Asterisk indicates the tumour belongs to group I in clustering analysis of Figure 2.
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DISCUSSION
Gene expression profiling has become an increasingly important
aid in the molecular diagnosis and classification of human
malignancies, including soft tissue sarcomas (Golub et al, 1999;
Alizadeh et al, 2000; Bittner et al, 2000; Perou et al, 2000; Nielsen
et al, 2002; Lee et al, 2003; Francis et al, 2007; Tschoep et al, 2007;
Elias et al, 2015). Although the existing classification permits soft
tissue tumours to be distinguished from one another, there is still
much room for improvement in the classification scheme.
Identification of new molecular subtypes will aid in the manage-
ment of the disease, which was well illustrated by the introduction
of the diagnostic category GIST and the development of new
targeted therapies specific to this class of tumours that have
revolutionised its treatment (Nishida et al, 2015). In this study, we
have attempted to identify molecular subtypes of leiomyosarcoma,
using an array designed to allow one to further investigate the
subgroupings proposed by Nielsen et al (2002). We have focused on
leiomyosarcomas of extra-uterine origins, as uterine leiomyosarcoma
represents a relatively distinct clinical entity and can be easily
identified from its site of origin (Amant et al, 2009; Linch et al, 2014).
When clustering analysis was performed in our tumour set
using the ‘leio-subclass’ genes reported by Nielsen et al (2002),
we similarly found two subgroups of leiomyosarcomas.
In addition, tumour clustering using a set of most varied genes
(169 genes) in our data set also gave rise to two groups of tumours
that very much matched the tumour groupings using the 18
‘leio-subclass’ gene set. These groups of tumours were defined by
the high expression of a cluster of 26 genes (Table 1). Sixteen
additional genes were new to the ‘leio-subclass’ gene cluster and it
is interesting to note that a number of these genes have structural
importance just like genes reported in Nielsen et al (2002) being
implicated in muscle structure and function that included
Calponin, laminin, actin and leiomodin. Also included in these
16 additional genes was the gene for D10S170 DNA fragment
(clone 563392, now called CCDC6 coiled-coil domain containing 6),
which was present immediately next to the ‘leio-subclass’ genes in
the gene dendrogram from Nielsen et al (2002) and also showed
similar expression pattern to these genes. Though its gene function
is still largely unknown, it has been suggested to have tumour
suppressor function. It is worth noting that COL4A1 and COL4A2
Table 1. List of genes in the cluster of 26 genes that defined the leiomyosarcoma subgrouping
Spot ID I.M.A.G.E. clone ID UniGene Cluster Symbol Name
774078 774078 Hs.519075 LMOD1 Leiomodin 1 (smooth muscle)
1473274 1473274 Hs.504687 MYL9 Elongation factor Tu family protein
502177 502177 Hs.460109 MYH11 Myosin, heavy polypeptide 11, smooth muscle
212621 212621 Hs.500483 ACTA2 Actin, alpha 2, smooth muscle, aorta
81289 81289 Hs.516105 ACTG2 Actin, gamma 2, smooth muscle, enteric
726779 726779 Hs.465929 CNN1 Calponin 1, basic, smooth muscle
197657 197657 Hs.436219 ALDH1B1 Aldehyde dehydrogenase 1 family, member B1
28218 28218 Hs.7195 GABRG2 Gamma-aminobutyric acid A receptor, gamma 2
769959 769959a Hs.508716 COL4A2 Collagen, type IV, alpha 2
491692 491692a Hs.17441 COL4A1 Collagen, type IV, alpha 1
1677204 1677204a Hs.356624 NID Nidogen 1
362059 362059 Hs.436367 LAMA3 Laminin, alpha 3
785744b 785744a Hs.494538 PTCH Patched homologue (Drosophila)
839736 839736a Hs.53454 CRYAB Crystallin, alpha B
868304 868304 Hs.500483 ACTA2 Actin, alpha 2, smooth muscle, aorta
593183 593183a Hs.5509 EVI2B Ecotropic viral integration site 2B
47475 47475a Hs.519702 CYFIP2 Cytoplasmic FMR1 interacting protein 2
759173b 759173a Hs.296049 MFAP4 Microfibrillar-associated protein 4
251019 251019a Hs.461086 CDH1 Cadherin 1, type 1, E-cadherin (epithelial)
121316b 121316a Hs.224012 JAG1 Jagged 1 (Alagille syndrome)
563392 563392a Hs.591360 CCDC6 Coiled-coil domain containing 6
212078b 212078a Hs.644352 ITGA1 Integrin, alpha 1
768292b 768292a Hs.304192 DSTN Destrin (actin depolymerising factor)
741880 741880a Hs.557097 PBX1 Pre-B-cell leukaemia transcription factor 1
40773 40773a Hs.584760 GNAZ Guanine nucleotide binding protein (G protein), alpha z polypeptide
161484b 161484a — — Multiple genes
NB: the refined group of 15 genes were shown as the top 15 genes in this table.
aGenes that were new to the ‘leio-subclass’ genes.
bClones that were found by DNA sequencing to have a sequence different from the one originally associated with the I.M.A.G.E. clone ID during sequence confirmation of the genes.
Table 2. Distribution of tumour grade vs tumour subgroup
Tumour subgroup
Group I Group II Total
Tumour grade
1 1 0 1
2 5 1 6
3 2 9 11
Total 8 10 18
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are two closely related genes located on the same chromosome.
COL4A2 gene is organised in a head-to-head conformation with
the other type IV collagen gene COL4A1, so that the gene pair
shares a common promoter. This supported the reliability of the
microarray data, as both genes were picked up and were clustered
next to each other in clustering analysis.
The tumour groupings using the most varied genes largely
matched with the groupings using the ‘leio-subclass’ genes, but
there was a small difference in the groupings that could have arisen
from the noise in the data. We might have included many genes in
the clustering using the most varied genes that are not relevant to
the ‘Calponin’ groupings. So clustering analysis was performed
using the cluster of 26 genes that defined the tumour subgroups,
and we obtained two groups that matched exactly with the two
groups from clustering using the ‘leio-subclass’ genes.
Nielsen et al (2002) reported that too few cases were available to
allow for meaningful comparison based on the histological findings
between the two groups. And within the limit of their study, clinical
features, such as tumour location, did not account for the separation
of the leiomyosarcomas into the two subgroups. They did not
comment directly on other clinical associations apart from the tumour
location. We have investigated possible association with various
clinical parameters, and we have found a statistically significant
association of the subgrouping of leiomyosarcomas with the tumour
grade. The histological grading of soft tissue sarcomas is determined
by an assessment of various factors, including differentiation
(pleomorphism of tumour cells), mitotic activity, degree of cellularity,
matrix formation and amount of necrosis (Trojani et al, 1984; Oliveira
and Nascimento, 2001). It is considered an important prognostic
factor for adult soft tissue sarcomas and has been used in guiding
patient management (Oliveira and Nascimento, 2001). However, a
consistent reproducible grading system can at times be difficult to
achieve (Oliveira and Nascimento, 2001). Genes identified from these
gene expression studies may aid in achieving better tumour grading,
and may be particularly useful in difficult cases.
We have further refined the gene list to a group of 15 genes that
could recapitulate the tumour subgroupings in our data set, and
have validated this gene list in an independent sarcoma set from
Baird et al (2005), where we also found a subgroup of tumours
defined by this group of genes. Unfortunately, associated clinical
data were not available and one could not assess the association of
tumour subgrouping with the tumour grade in this data set.
Guo et al (2015) have recently used gene expression profiling to
identify three molecular subtypes of leiomyosarcoma using formalin-
fixed, paraffin-embedded tumour samples () following their earlier
study (Beck et al, 2010): subtype I was the subgroup that was relatively
well-defined molecularly and had higher expression of genes enriched
for processes that included muscle contraction, muscle system
processes and cytoskeleton organisation. Subtype II had less muscle-
specific gene expression than subtype I. Guo et al have proposed the
use of LMOD1 (replacing CASQ2 proposed in their earlier study)
together with the proteins ACTG2, SLMAP, MYLK and CFL2 to be
the panel of subtype I immunohistochemical biomarkers. They have
also proposed the use of ARL4C to be the subtype II biomarker. They
have not proposed any immunohistochemical markers for subtype III.
Subtype III appeared to be less well-defined molecularly and when
they attempted to investigate if they could find these three subtypes in
another publicly available gene expression data set, they noted that
their subtypes I and II could be significantly reproduced in this data
set, but not subtype III. However, they noted from related clinical
information that clinically subtype III tumours were mostly of uterine
origin (92% in their own tumour set) and uterine leiomysarcoma was
significantly associated with subtype III. In our study, we have found
two distinct molecular subgroups of leiomyosarcomas. As we did not
include tumours of uterine origin in our study, it is expected that we
would not find a subgroup that corresponded to their subtype III. Our
group I was defined by a cluster of 26 genes (Table 1) that included
many genes implicated in muscle structure and function. We noted
that LMOD1 and ACTG2 from the panel of five genes whose encoded
proteins they proposed to be used as immunohistochemical markers
for subtype I were also found in our 26 group I defining gene list. In
fact, further investigation showed that the majority of the genes in our
group I defining gene list were ranked highly in their list of genes that
had a higher expression in subtype I vs other subtypes, including
LMOD1, MYL9, MYH11, ACTA2, ACTG2, CNN1, ALDH1B1,
COL4A2, COL4A1, CRYAB, CYFIP2, MFAP4, CDH1, JAG1, DSTN
and GNAZ. They have proposed the use of ARL4C as immunohis-
tochemical marker for subtype II, but this gene was not included in
our array. On the other hand, a cluster of four genes that correlated
with and had higher expression in our group II (GJA1, COL5A2,
THBS2 and MFAP2) were also found to be highly ranked in their list
of significant genes that had a higher expression in subtype II vs other
subtypes. In fact, the first three of these genes were ranked higher
(more significantly associated with subtype II) than the ARL4C, whose
protein they had chosen to be the immunohistochemical marker for
subtype II in their study. It is perhaps worth noting that the use of a
single-protein ARL4C to be subtype II marker and its use in
classifying tumours as subtype II or not, using immunohistochemistry
had quite a significant error rate (31% of their tumour samples were
misclassified into a different subtype than the original classification
based on gene expression profiles), so perhaps a combination of
markers would help to improve the accuracy of an immunohisto-
chemical classification. Class comparison analysis was also performed
to identify statistically significant genes associated with our two
subgroups, we got similar genes to the clusters of group-defining
genes mentioned above that also corresponded to their significant
genes for subtype I and II, respectively. On the whole, our findings
suggested that our group I corresponded to their subtype I; and our
group II corresponded to their subtype II; providing further support
to the existence of these two molecular subgroups (in a UK data set).
Though they have found that low-grade tumours were more frequent
in their subtype I, this did not reach statistical significance in their
data set; whereas in our data set, we have found a statistically
significant association of the subgroups with tumour grade, with
group I being associated with lower grade.
Chibon et al (2010) has reported on identifying a gene expression
signature, which they have called CINSARC—Complexity INdex in
SARComa, that was found to be associated with metastatic outcome
in a mixture of different soft tissue sarcomas. The CINSARC gene set
is composed of 67 genes related to mitosis and chromosomal stability.
We have compared the CINSARC genes with the statistically
significant genes associated with our two subgroups and found no
overlap in these genes. It is perhaps not too surprising, as although the
authors found that the CINSARC genes could predict metastatic
behaviour in soft tissue sarcomas in general, the authors had also done
a survival analysis in their validation set of leiomysarcomas and
reported that they could not find a statistically significant difference in
metastasis-free survival in their two subgroups (Chibon et al, 2010).
To conclude, we have identified two molecular subgroups of
leiomyosarcomas, one group being characterised by the high level of
expression of a cluster of 26 genes that included many genes in the
‘leio-subclass’ genes, and provided confirmation of the findings of
Nielsen et al (2002) in an independent sarcoma set. We have also
identified additional genes to the original ‘leio-subclass’ gene cluster that
contributed to sub-classification of leiomyosarcoma. We have also
investigated the clinical significance of the groupings and found an
association with tumour grade. We have further refined our gene list to
a group of 15 genes that could recapitulate the tumour subgroupings in
our data set, and have validated this in an independent sarcoma set
from Baird et al (2005). Further comparison with a recently published
data set suggested that our findings also matched with two molecular
subgroups in their data set (Guo et al, 2015). Cross-study comparisons
and analyses of expression data sets were renowned for often giving rise
to discrepant or completely different results. Quite remarkably, our
BRITISH JOURNAL OF CANCER Gene profiling identifies leiomyosarcoma subgroups
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findings suggested that the two distinct molecular subgroups identified
here could be found across four independent data sets, providing strong
support for their existence. Our findings will aid in achieving a better
classification of leiomyosarcomas and eventually lead to a better
management of the disease and more individualised therapies for
sarcoma patients.
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